68.88 +0.07 (0.10%)
Before hours: 5:33AM EDT
|Bid||0.00 x 2200|
|Ask||69.47 x 1200|
|Day's range||68.62 - 69.61|
|52-week range||60.89 - 85.97|
|Beta (5Y monthly)||0.66|
|PE ratio (TTM)||N/A|
|Forward dividend & yield||2.72 (3.94%)|
|Ex-dividend date||14 Sep 2020|
|1y target est||N/A|
Diodes Incorporated (Nasdaq: DIOD) today reported its financial results for the second quarter ended June 30, 2020.
The coalition of more than 30 state attorneys general called on the government to act or allow states to do so, saying in a letter to U.S. health agencies that Gilead "has not established a reasonable price" for remdesivir. "Gilead should not profit from the pandemic and it should be pushed to do more to help more people," the letter said.
Gilead Sciences (NASDAQ: GILD) beat Wall Street estimates when the big biotech announced its first-quarter results in late April. Last week, Gilead announced second-quarter results that were below analysts' expectations. Gilead has been in the news quite a bit in recent months thanks to the clinical success for its COVID-19 therapy remdesivir.